Cite
HARVARD Citation
Bi, Y. et al. (2019). Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Annals of oncology. pp. 644-651. [Online].